The frequent expression of neurotensin receptors (NT-R) in primaries of pancreatic ductal carcinomas has triggered the development of radioactive neurotensin analogs for possible in vivo targeting of these tumors. The gene discussed is NTSR1; the disease is pancreatic ductal adenocarcinoma.